{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "cabotegravir",
                    "comparison to": "TDF-FTC",
                    "events": "4",
                    "total person-years": "1956",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06-0.52"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "cabotegravir",
                    "comparison to": "TDF-FTC",
                    "events": "4",
                    "total person-years": "1956",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06-0.52"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "cabotegravir",
                    "comparison to": "TDF-FTC",
                    "events": "4",
                    "total person-years": "1956",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06-0.52"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "cabotegravir",
                    "comparison to": "TDF-FTC",
                    "events": "4",
                    "total person-years": "1956",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06-0.52"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "cabotegravir",
                    "comparison to": "TDF-FTC",
                    "events": "4",
                    "total person-years": "1956",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06-0.52"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "cabotegravir",
                    "comparison to": "TDF-FTC",
                    "events": "4",
                    "total person-years": "1956",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06-0.52"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "cabotegravir",
                    "comparison to": "TDF-FTC",
                    "events": "4",
                    "total person-years": "1956",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06-0.52"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "cabotegravir",
                    "comparison to": "TDF-FTC",
                    "events": "4",
                    "total person-years": "1956",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06-0.52"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "cabotegravir",
                    "comparison to": "TDF-FTC",
                    "events": "4",
                    "total person-years": "1956",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06-0.52"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "TDF-FTC",
                    "comparison to": "cabotegravir",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3-2.57"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[1.85, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "TDF-FTC",
                    "comparison to": "cabotegravir",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3-2.57"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[1.85, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "TDF-FTC",
                    "comparison to": "cabotegravir",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3-2.57"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[1.85, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "TDF-FTC",
                    "comparison to": "cabotegravir",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3-2.57"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[1.85, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "TDF-FTC",
                    "comparison to": "cabotegravir",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3-2.57"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[1.85, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "TDF-FTC",
                    "comparison to": "cabotegravir",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3-2.57"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[1.85, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "TDF-FTC",
                    "comparison to": "cabotegravir",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3-2.57"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[1.85, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "TDF-FTC",
                    "comparison to": "cabotegravir",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3-2.57"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[1.85, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "group": "TDF-FTC",
                    "comparison to": "cabotegravir",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3-2.57"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[1.85, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "overall",
                    "group": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "overall",
                    "group": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "overall",
                    "group": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "overall",
                    "group": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "overall",
                    "group": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "overall",
                    "group": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "overall",
                    "group": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "overall",
                    "group": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "overall",
                    "group": "TDF-FTC",
                    "events": "36",
                    "total person-years": "1942",
                    "HIV incidence": "1.85%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.20, 0.12]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "<25 years",
                    "group": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "HIV incidence": "2.34%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.35, 0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "<25 years",
                    "group": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "HIV incidence": "2.34%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.35, 0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "<25 years",
                    "group": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "HIV incidence": "2.34%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.35, 0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "<25 years",
                    "group": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "HIV incidence": "2.34%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.35, 0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "<25 years",
                    "group": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "HIV incidence": "2.34%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.35, 0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "<25 years",
                    "group": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "HIV incidence": "2.34%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.35, 0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "<25 years",
                    "group": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "HIV incidence": "2.34%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.35, 0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "<25 years",
                    "group": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "HIV incidence": "2.34%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.35, 0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "<25 years",
                    "group": "TDF-FTC",
                    "events": "20",
                    "total person-years": "851",
                    "HIV incidence": "2.34%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.35, 0.17]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "\u226525 years",
                    "group": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "HIV incidence": "1.47%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.09, 0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "\u226525 years",
                    "group": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "HIV incidence": "1.47%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.09, 0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "\u226525 years",
                    "group": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "HIV incidence": "1.47%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.09, 0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "\u226525 years",
                    "group": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "HIV incidence": "1.47%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.09, 0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "\u226525 years",
                    "group": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "HIV incidence": "1.47%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.09, 0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "\u226525 years",
                    "group": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "HIV incidence": "1.47%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.09, 0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "\u226525 years",
                    "group": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "HIV incidence": "1.47%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.09, 0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "\u226525 years",
                    "group": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "HIV incidence": "1.47%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.09, 0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "age",
                    "sub-subgroup": "\u226525 years",
                    "group": "TDF-FTC",
                    "events": "16",
                    "total person-years": "1091",
                    "HIV incidence": "1.47%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.09, 0.09]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "DMPA",
                    "group": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "HIV incidence": "2.10%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.30, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "DMPA",
                    "group": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "HIV incidence": "2.10%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.30, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "DMPA",
                    "group": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "HIV incidence": "2.10%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.30, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "DMPA",
                    "group": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "HIV incidence": "2.10%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.30, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "DMPA",
                    "group": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "HIV incidence": "2.10%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.30, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "DMPA",
                    "group": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "HIV incidence": "2.10%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.30, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "DMPA",
                    "group": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "HIV incidence": "2.10%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.30, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "DMPA",
                    "group": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "HIV incidence": "2.10%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.30, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "DMPA",
                    "group": "TDF-FTC",
                    "events": "21",
                    "total person-years": "1000",
                    "HIV incidence": "2.10%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.30, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "NET-EN",
                    "group": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "HIV incidence": "3.30%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.57, 0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "NET-EN",
                    "group": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "HIV incidence": "3.30%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.57, 0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "NET-EN",
                    "group": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "HIV incidence": "3.30%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.57, 0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "NET-EN",
                    "group": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "HIV incidence": "3.30%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.57, 0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "NET-EN",
                    "group": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "HIV incidence": "3.30%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.57, 0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "NET-EN",
                    "group": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "HIV incidence": "3.30%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.57, 0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "NET-EN",
                    "group": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "HIV incidence": "3.30%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.57, 0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "NET-EN",
                    "group": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "HIV incidence": "3.30%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.57, 0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "NET-EN",
                    "group": "TDF-FTC",
                    "events": "6",
                    "total person-years": "182",
                    "HIV incidence": "3.30%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.57, 0.22]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Implant",
                    "group": "TDF-FTC",
                    "events": "8",
                    "total person-years": "607",
                    "HIV incidence": "1.32%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.06]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Implant",
                    "group": "TDF-FTC",
                    "events": "8",
                    "total person-years": "607",
                    "HIV incidence": "1.32%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.06]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Implant",
                    "group": "TDF-FTC",
                    "events": "8",
                    "total person-years": "607",
                    "HIV incidence": "1.32%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.06]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Implant",
                    "group": "TDF-FTC",
                    "events": "8",
                    "total person-years": "607",
                    "HIV incidence": "1.32%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.06]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Implant",
                    "group": "TDF-FTC",
                    "events": "8",
                    "total person-years": "607",
                    "HIV incidence": "1.32%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.06]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Implant",
                    "group": "TDF-FTC",
                    "events": "8",
                    "total person-years": "607",
                    "HIV incidence": "1.32%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.06]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Other",
                    "group": "TDF-FTC",
                    "events": "1",
                    "total person-years": "152",
                    "HIV incidence": "0.66%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.32]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Other",
                    "group": "TDF-FTC",
                    "events": "1",
                    "total person-years": "152",
                    "HIV incidence": "0.66%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.32]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Other",
                    "group": "TDF-FTC",
                    "events": "1",
                    "total person-years": "152",
                    "HIV incidence": "0.66%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.32]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Other",
                    "group": "TDF-FTC",
                    "events": "1",
                    "total person-years": "152",
                    "HIV incidence": "0.66%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.32]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Other",
                    "group": "TDF-FTC",
                    "events": "1",
                    "total person-years": "152",
                    "HIV incidence": "0.66%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.32]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "contraceptive method",
                    "sub-subgroup": "Other",
                    "group": "TDF-FTC",
                    "events": "1",
                    "total person-years": "152",
                    "HIV incidence": "0.66%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.32]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": "\u226430 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "27",
                    "total person-years": "1447",
                    "HIV incidence": "1.87%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.29, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": "\u226430 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "27",
                    "total person-years": "1447",
                    "HIV incidence": "1.87%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.29, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": "\u226430 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "27",
                    "total person-years": "1447",
                    "HIV incidence": "1.87%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.29, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": "\u226430 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "27",
                    "total person-years": "1447",
                    "HIV incidence": "1.87%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.29, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": "\u226430 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "27",
                    "total person-years": "1447",
                    "HIV incidence": "1.87%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.29, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": "\u226430 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "27",
                    "total person-years": "1447",
                    "HIV incidence": "1.87%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.29, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": "\u226430 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "27",
                    "total person-years": "1447",
                    "HIV incidence": "1.87%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[0.29, 0.16]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": ">30 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "9",
                    "total person-years": "495",
                    "HIV incidence": "1.82%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.05]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": ">30 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "9",
                    "total person-years": "495",
                    "HIV incidence": "1.82%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.05]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": ">30 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "9",
                    "total person-years": "495",
                    "HIV incidence": "1.82%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.05]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": ">30 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "9",
                    "total person-years": "495",
                    "HIV incidence": "1.82%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.05]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": ">30 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "9",
                    "total person-years": "495",
                    "HIV incidence": "1.82%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.05]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": ">30 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "9",
                    "total person-years": "495",
                    "HIV incidence": "1.82%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.05]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT analysis",
                    "analysis type": "cabotegravir effectiveness",
                    "subgroup": "body-mass index",
                    "sub-subgroup": ">30 kg/m\u00b2",
                    "group": "TDF-FTC",
                    "events": "9",
                    "total person-years": "495",
                    "HIV incidence": "1.82%"
                },
                "measures": "[HIV incidence, HR]",
                "outcomes": "[., 0.05]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "yes"
        }
    ],
    "total_extracted_claims": 11,
    "total_ground_truth_claims": 9,
    "number_of_matches": 3
}